Sparian Biosciences is a bio-pharmaceutical company focusing on discovering and developing new therapies to target the central nervous system (CNS).
Sparian was co-founded by Gavril Pasternak, MD PhD and Jeff Reich, MD to develop therapeutics targeting the brain through innovative science and novel drug discovery.
Our first program targets the AEA receptor with a new class of agents, the arylepoxamides. The lead candidate is SBS-1000, a novel new analgesic discovered in the Pasternak Lab, which demonstrates potent analgesia, but lacks the side effects associated with traditional highly potent pain relievers. Development of SBS-1000 through a proof of concept phase 1b is funded via a NIH/NIDA grant.